SEC investigating Illumina over acquisition of cancer test developer Grail

  • 📰 CNBC
  • ⏱ Reading Time:
  • 7 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 6%
  • Publisher: 72%

Sverige Nyheter Nyheter

Sverige Senaste nytt,Sverige Rubriker

Illumina's acquisition of cancer test developer Grail has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.

Last month, the SEC informed Illumina about the probe and requested documents and communications related to the. The agency also asked for statements and disclosures about the "conduct and compensation" of certain members of both Illumina and Grail's management, according to the filing.

Illumina's Grail deal has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.

Vi har sammanfattat den här nyheten så att du kan läsa den snabbt. Om du är intresserad av nyheterna kan du läsa hela texten här. Läs mer:

 /  🏆 12. in SE
 

Tack för din kommentar. Din kommentar kommer att publiceras efter att ha granskats.

Sverige Senaste nytt, Sverige Rubriker